{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:29:13Z","timestamp":1770964153653,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ontario Institute for Cancer Research [Smarter Imaging Program and High Impact Clinical Trial (HICT) Program]"},{"name":"Province of Ontario"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","nucmedbio.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.nucmedbio.2014.09.011","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T04:56:04Z","timestamp":1413262564000},"page":"78-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I\/II clinical trial of 111In-BzDTPA-pertuzumab"],"prefix":"10.1016","volume":"42","author":[{"given":"Karen","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrad","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan J.","family":"Done","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark N.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0005","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0010","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/bcr1612","article-title":"HER2 therapy: molecular mechanisms of trastuzumab resistance","volume":"8","author":"Nahta","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0020","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/sj.clpt.6100096","article-title":"Molecular imaging as a tool for personalized and targeted anticancer therapy","volume":"81","author":"McLarty","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","article-title":"Herceptin: mechanisms of action and resistance","volume":"232","author":"Nahta","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0030","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00262-005-0058-x","article-title":"Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab","volume":"55","author":"Adams","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0035","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0045","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2967\/jnumed.109.062224","article-title":"Micro-SPECT\/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts","volume":"50","author":"McLarty","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0050","first-page":"1023","article-title":"Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an Auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer","volume":"47","author":"Reilly","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/rpd\/ncr003","article-title":"Organ dose conversion coefficients based on a voxel mouse model and MCNP code for external photon irradiation","volume":"148","author":"Zhang","year":"2012","journal-title":"Radiat Prot Dosimetry"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0060","series-title":"Pharmacokinetics","first-page":"445","article-title":"Estimation of areas","author":"Appendix","year":"1982"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0065","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0120","series-title":"Drugs directorate guidelines for toxicologic evaluation","author":"Anonymous","year":"1995"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0075","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0883-2889(92)90214-Y","article-title":"In vitro stability of EDTA and DTPA immunoconjugates of monoclonal antibody 2G3 labeled with indium-111","volume":"43","author":"Reilly","year":"1992","journal-title":"Int J Rad Appl Instrum A"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0080","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.2005.03.184","article-title":"Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer","volume":"23","author":"Agus","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0085","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1021\/ac101901x","article-title":"Synthesis of a functional metal-chelating polymer and steps toward quantitative mass cytometry bioassays","volume":"82","author":"Majonis","year":"2010","journal-title":"Anal Chem"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0090","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1021\/bc100261d","article-title":"Effects of charge on antibody tissue distribution and pharmacokinetics","volume":"21","author":"Boswell","year":"2010","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0095","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2165\/00003088-199528020-00004","article-title":"Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions","volume":"28","author":"Reilly","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/0008-5472.CAN-06-2363","article-title":"[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts","volume":"67","author":"Persson","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0125","series-title":"Monoclonal antibody and peptide-targeted radiotherapy of cancer","first-page":"473","article-title":"Dosimetry for targeted radiotherapy","author":"Shen","year":"2010"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0130","author":"Anonymous"},{"key":"10.1016\/j.nucmedbio.2014.09.011_bb0115","first-page":"885","article-title":"Procedure guideline for tumor imaging with 18F-FDG PET\/CT 1.0","volume":"47","author":"Delbeke","year":"2006","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805114005204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805114005204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T10:52:07Z","timestamp":1538131927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805114005204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0969805114005204"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2014.09.011","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I\/II clinical trial of 111In-BzDTPA-pertuzumab","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2014.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}